Details of the Drug

General Information of Drug (ID: DMP2SGN)

Drug Name
Dabelotine
Synonyms Dabelotine mesilate; S-12024; S-12024-2
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 262.35
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C15H22N2O2
IUPAC Name
2-[(1-methyl-3,4-dihydro-2H-quinolin-8-yl)oxymethyl]morpholine
Canonical SMILES
CN1CCCC2=C1C(=CC=C2)OCC3CNCCO3
InChI
InChI=1S/C15H22N2O2/c1-17-8-3-5-12-4-2-6-14(15(12)17)19-11-13-10-16-7-9-18-13/h2,4,6,13,16H,3,5,7-11H2,1H3
InChIKey
VXQWMLATWQSCBE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
177949
CAS Number
118976-38-8
TTD ID
D01FDL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor (ADR) TTVIREA NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002175)
2 US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.